1.02
+0(+0.00%)
Currency In USD
| Previous Close | 1.02 |
| Open | 1.02 |
| Day High | 1.04 |
| Day Low | 0.98 |
| 52-Week High | 7.29 |
| 52-Week Low | 0.68 |
| Volume | 6.3M |
| Average Volume | 11.52M |
| Market Cap | 99.95M |
| PE | -1.29 |
| EPS | -0.79 |
| Moving Average 50 Days | 3.1 |
| Moving Average 200 Days | 3.84 |
| Change | 0 |
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
GlobeNewswire Inc.
Sep 30, 2025 9:30 AM GMT
Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0226). Improvement in King
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
GlobeNewswire Inc.
Sep 15, 2025 11:30 AM GMT
Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofit
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
GlobeNewswire Inc.
Jul 22, 2025 12:00 PM GMT
Topline results expected in the third quarter of 2025.SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-